<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Marrouche, Nassir</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">DE-MRI Quantification of Atrial Fibrosis Predicts Ablation Outcome in Patients with Atrial Fibrillation</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-06-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-15</style></pages><abstract><style  face="normal" font="default" size="100%">Previous studies demonstrated that the structural changes to the heart that are associated with atrial fibrillation (AF) can be quantified using DE-MRI [Oakes RS et al. Circulation 2009]. This article presents data from the Delayed-Enhancement Magnetic Resonance Imaging (DE-MRI) Determinant of Successful Radiofrequency Catheter Ablation for Atrial Fibrillation trial [DECAAF; NCT01150214]. The DECAAF trial tested the hypothesis that DE-MRI can be used to determine the amount of left atrial fibrosis and/or remodeling, which predicts the patient's response to AF ablation.</style></abstract><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>